Targeted Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Targeted therapy represents one of the most significant advances in cancer medicine over the past three decades — a paradigm shift from the broad, indiscriminate cytotoxicity of conventional chemotherapy towards precision oncology: drugs designed to interact specifically with molecular targets that drive tumour growth, survival, and spread. Rather than killing all rapidly dividing cells (healthy and cancerous alike), targeted therapies interfere with precise proteins, genes, enzymes, or signalling pathways that cancer cells depend on disproportionately — resulting in a more selective anti-tumour effect and a substantially different (and often more tolerable) side effect profile compared to traditional chemotherapy.

The foundation of targeted therapy lies in an understanding of cancer biology at the molecular level. Cancers arise and progress through the accumulation of genetic mutations and epigenetic alterations that activate growth-promoting oncogenes, deactivate tumour suppressor genes, and rewire the cell's internal signalling networks. Many of these alterations produce proteins that are structurally or functionally distinct from their normal counterparts — making them ideal drug targets. The success of imatinib (Gleevec) in chronic myelogenous leukaemia (CML), trastuzumab (Herceptin) in HER2-positive breast cancer, and erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) established proof of concept and launched a new era of molecular oncology.

Today, more than 100 targeted therapy agents have received regulatory approval globally (FDA, EMA, and national regulatory bodies), and targeted therapy is now the standard of care — either alone or in combination with chemotherapy, immunotherapy, or hormonal therapy — for dozens of cancer types. The field continues to evolve rapidly, with new targets identified, new drug classes developed, and combination strategies refined through an expanding portfolio of clinical trials.

Targeted therapy works best when patients are selected based on biomarker testing — confirming that the specific target is present (or overexpressed, amplified, or mutated) in the patient's tumour. This matching of therapy to tumour biology is the essence of personalised cancer care.

Targeted therapies have transformed the treatment landscape for a wide range of cancers. The following highlights the most well-established clinical applications:

Breast Cancer

• HER2-positive breast cancer: Trastuzumab (Herceptin), pertuzumab, trastuzumab emtansine (T-DM1), and trastuzumab deruxtecan (T-DXd) target the HER2 receptor tyrosine kinase, which is amplified in approximately 20% of breast cancers. HER2-targeted therapy has transformed this previously aggressive subtype from one of the worst prognoses to one of the most treatable.
• HR-positive, HER2-negative advanced breast cancer: CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) in combination with aromatase inhibitors are now standard first-line therapy for hormone receptor-positive metastatic breast cancer, extending progression-free survival from approximately 14 months to over 27 months.
• BRCA-mutated breast cancer: PARP inhibitors (olaparib, talazoparib) are approved for germline BRCA1/2-mutated HER2-negative metastatic breast cancer following prior chemotherapy.

Lung Cancer (NSCLC)

• EGFR-mutant NSCLC: EGFR inhibitors — first generation (gefitinib, erlotinib), second generation (afatinib), and third generation (osimertinib, alectinib) — are standard first-line therapy for NSCLC with activating EGFR mutations (exon 19 deletion, L858R). Osimertinib is currently preferred for its CNS penetration and efficacy against T790M resistance mutation.
• ALK-rearranged NSCLC: ALK inhibitors (alectinib, brigatinib, lorlatinib) achieve response rates of 80–90% in ALK-positive NSCLC and have replaced chemotherapy as first-line treatment.
• ROS1, BRAF V600E, MET, RET, KRAS G12C NSCLC: Multiple targetable driver mutations in NSCLC now have approved treatments, making molecular profiling of all advanced NSCLC mandatory.

Haematological Malignancies

• CML (Chronic Myelogenous Leukaemia): BCR-ABL1 tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, ponatinib) have revolutionised CML, converting it from a disease with median survival of 4–5 years to one in which many patients achieve treatment-free remission and near-normal life expectancy.
• CLL and other B-cell lymphomas: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib), BCL-2 inhibitors (venetoclax), and PI3K inhibitors.

Other Cancers

• Colorectal cancer (KRAS wild-type): Anti-EGFR monoclonal antibodies (cetuximab, panitumumab).
• Kidney cancer (RCC): VEGF/mTOR pathway inhibitors (sunitinib, pazopanib, cabozantinib, everolimus).
• Melanoma (BRAF V600E): BRAF + MEK inhibitor combinations (vemurafenib + cobimetinib; dabrafenib + trametinib) achieve rapid tumour response in 60–70% of patients.
• Ovarian cancer (BRCA-mutated or HRD): PARP inhibitors (olaparib, niraparib, rucaparib) as maintenance therapy after platinum-based chemotherapy.
• Gastrointestinal stromal tumours (GIST): Imatinib (c-KIT/PDGFR targeting) has converted GIST from a virtually untreatable cancer to one with 5-year survival exceeding 75% in localised disease.

Eligibility for targeted therapy is fundamentally determined by the presence of the specific molecular target in the patient's tumour — not simply by cancer type or stage. Comprehensive biomarker testing is therefore a prerequisite for prescribing targeted therapy, and this testing has become a central component of modern oncology workup.

Biomarker Testing Approaches

• Immunohistochemistry (IHC): Detects overexpression of target proteins (e.g., HER2 protein, PD-L1 expression). Inexpensive and widely available but semi-quantitative.
• Fluorescence In Situ Hybridisation (FISH): Detects gene amplification (HER2) and chromosomal rearrangements (ALK, ROS1 fusions). More sensitive than IHC for copy number changes.
• Next-Generation Sequencing (NGS) — Tumour Molecular Profiling: Simultaneously analyses hundreds of cancer-related genes for mutations, fusions, copy number alterations, and microsatellite instability (MSI). Comprehensive genomic profiling (CGP) panels (e.g., Foundation One CDx, Guardant 360 CDx, MSK-IMPACT) are now widely used for solid tumours. NGS identifies targetable alterations and may reveal options for clinical trial enrolment.
• Liquid Biopsy (Cell-Free DNA): Detection of tumour-derived circulating DNA (ctDNA) in blood plasma. Increasingly used for treatment monitoring, resistance detection (e.g., T790M EGFR mutation on liquid biopsy), and when tissue biopsy is not feasible.
• FISH/RT-PCR for haematological malignancies: BCR-ABL1 quantification by RT-PCR is the gold standard for monitoring CML response to TKI therapy.

General Eligibility Criteria

• Confirmed cancer diagnosis (pathological specimen with histological or cytological verification).
• Documented presence of the specific targetable biomarker or molecular alteration in the tumour.
• Adequate organ function: hepatic, renal, and cardiac function within specified limits (as each drug has specific organ-toxicity risks).
• No significant drug-drug interactions with ongoing medications (particularly relevant for oral targeted therapies metabolised by CYP450 enzymes).
• No prior treatment with the same or related agent that has resulted in confirmed resistance (unless a next-generation agent is available to overcome specific resistance mutations).
• Female patients of childbearing potential must use effective contraception throughout treatment and for a defined period afterward (most targeted therapies are teratogenic).

Targeted therapy is not a single drug but a diverse class of agents grouped by their mechanism of action, target, and molecular structure. The major categories are:

Small Molecule Kinase Inhibitors

Small molecules that penetrate the cell membrane and inhibit intracellular signalling kinases. Most are taken orally (tablets or capsules). Major subcategories include:

• EGFR Inhibitors: Gefitinib, erlotinib, afatinib, osimertinib — for EGFR-mutant NSCLC and head & neck cancers.
• BCR-ABL1 Inhibitors (TKIs): Imatinib, dasatinib, nilotinib, bosutinib, ponatinib, asciminib — for CML and Philadelphia chromosome-positive ALL.
• ALK/ROS1/MET Inhibitors: Crizotinib, alectinib, brigatinib, ceritinib, lorlatinib, capmatinib — for rearranged NSCLC.
• BRAF/MEK Inhibitors: Vemurafenib, dabrafenib (BRAF); cobimetinib, trametinib, binimetinib (MEK) — for BRAF V600E melanoma, NSCLC, thyroid cancer.
• CDK4/6 Inhibitors: Palbociclib, ribociclib, abemaciclib — for HR+ HER2- breast cancer.
• BTK Inhibitors: Ibrutinib, acalabrutinib, zanubrutinib — for CLL, MCL, Waldenstrom macroglobulinaemia.
• PARP Inhibitors: Olaparib, niraparib, rucaparib, talazoparib — for BRCA-mutated breast, ovarian, prostate, pancreatic cancers.

Monoclonal Antibodies (mAbs)

Large proteins that bind to specific targets on the tumour cell surface or in the tumour microenvironment. Administered intravenously or subcutaneously.

• Anti-HER2: Trastuzumab, pertuzumab, margetuximab.
• Anti-VEGF/VEGFR: Bevacizumab (anti-VEGF ligand), ramucirumab (anti-VEGFR2) — inhibit tumour angiogenesis.
• Anti-EGFR: Cetuximab, panitumumab — for KRAS wild-type colorectal cancer and head & neck cancer.
• Anti-CD20: Rituximab, obinutuzumab, ofatumumab — for B-cell lymphomas and CLL.

Antibody-Drug Conjugates (ADCs)

A monoclonal antibody linked to a potent cytotoxic payload (warhead), delivering chemotherapy precisely to tumour cells expressing the target antigen. Increasingly important class including trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-DXd), enfortumab vedotin, sacituzumab govitecan.

Hormone Receptor Antagonists

For hormone-driven cancers: aromatase inhibitors (letrozole, anastrozole, exemestane), selective oestrogen receptor degraders (SERDs — fulvestrant, elacestrant), anti-androgens (enzalutamide, apalutamide, darolutamide) for prostate cancer.

mTOR Inhibitors

Everolimus, temsirolimus — used for kidney cancer, certain breast cancer subtypes, and neuroendocrine tumours.

Targeted therapy has produced some of the most dramatic improvements in cancer outcomes ever recorded in oncology. The benefits extend across multiple dimensions: survival, quality of life, and the fundamental understanding of cancer as a manageable chronic disease for many patients.

• Remarkable efficacy in biomarker-selected patients: In the right patient, response rates of 60–90% are achievable — far exceeding those of conventional chemotherapy (typically 20–40% in comparable settings). Osimertinib in EGFR-mutant NSCLC achieves a median progression-free survival of 18.9 months; alectinib in ALK+ NSCLC achieves 34 months — versus 4–6 months with chemotherapy for similar patients.
• Oral administration: Most small molecule targeted agents are taken as once- or twice-daily oral tablets, allowing treatment at home without the need for hospital infusion appointments. This dramatically improves convenience and quality of life.
• More selective toxicity: By targeting cancer-specific or cancer-enriched pathways, targeted therapies generally cause less collateral damage to rapidly dividing healthy tissues (hair follicles, gastrointestinal mucosa, bone marrow) compared to conventional chemotherapy. Many patients maintain near-normal quality of life during treatment.
• Chronic disease management: For cancers like CML, where BCR-ABL TKIs produce deep molecular remissions, many patients effectively live with their cancer as a chronic, manageable condition. Some patients with sustained deep molecular response achieve treatment-free remission — stopping therapy indefinitely while remaining disease-free.
• Synergy with other modalities: Targeted therapies are increasingly combined with immunotherapy (checkpoint inhibitors), chemotherapy, or hormone therapy to achieve synergistic anti-tumour effects and delay resistance.
• CNS penetration (newer agents): Third-generation EGFR inhibitors (osimertinib) and ALK inhibitors (alectinib, lorlatinib) achieve high CNS drug concentrations, effectively treating brain metastases — a major advance in cancers that frequently metastasise to the brain.
• Biomarker-driven clinical trial opportunities: Molecular profiling opens access to clinical trials of novel agents targeting specific alterations, including basket trials and umbrella trials that match patients to treatments based on their tumour's molecular fingerprint regardless of cancer type.

While targeted therapies are generally better tolerated than chemotherapy, they carry their own characteristic side effect profiles determined by the specific molecular pathways they inhibit — in normal healthy tissues as well as in cancer cells. Side effects are typically class-specific and often manageable, but some are serious and require prompt recognition and intervention.

Class-Specific Side Effects

• EGFR inhibitors: Acneiform rash (70–80% of patients) — a characteristic pustular rash on the face, chest, and back that paradoxically correlates with treatment efficacy. Also: paronychia (nail fold inflammation), dry skin, mucositis, diarrhoea, and rare but serious interstitial lung disease (pneumonitis, 1–5%).
• HER2-targeted therapy (trastuzumab): Cardiac toxicity — reduction in left ventricular ejection fraction (LVEF) occurs in 5–15% of patients, usually asymptomatic and reversible on drug cessation. Requires regular echocardiographic monitoring (every 3 months during treatment).
• CDK4/6 inhibitors: Neutropenia is the most common dose-limiting toxicity (grade 3/4 neutropenia in 50–75%), requiring dose delays or reductions. Also: fatigue, anaemia, infections, and QTc prolongation (ribociclib).
• BCR-ABL TKIs (imatinib): Oedema (periorbital, peripheral), nausea, muscle cramps, bone pain, myelosuppression. Newer generation TKIs (ponatinib) carry cardiovascular risks (arterial thrombosis, hypertension).
• PARP inhibitors: Nausea, fatigue, anaemia, and thrombocytopenia. Risk of MDS/AML (myelodysplastic syndrome/acute myeloid leukaemia) with long-term use (1–3%).
• BRAF/MEK inhibitors: Cutaneous squamous cell carcinoma and keratoacanthomas (BRAF inhibitors alone, reduced by MEK inhibitor combination), photosensitivity, pyrexia (fever — especially dabrafenib + trametinib, occurring in 50–60% of patients), and retinal toxicity (MEK inhibitors).
• BTK inhibitors: Bleeding (antiplatelet effect), atrial fibrillation, hypertension, arthralgias, diarrhoea.
• Anti-VEGF (bevacizumab): Hypertension, proteinuria, wound healing impairment, rare but serious gastrointestinal perforation, arterial thromboembolic events.

Resistance

Virtually all targeted therapies eventually encounter tumour resistance — the cancer evolves new mutations or activates alternative signalling pathways to escape the drug. Resistance may be primary (intrinsic, present from the start) or acquired (developing during treatment). Serial monitoring with liquid biopsy (ctDNA) enables early detection of resistance mutations, allowing timely switch to next-generation agents or alternative strategies.

Patients receiving targeted therapy require structured, regular monitoring to assess treatment response, detect toxicities early, and identify resistance. The specific follow-up schedule is determined by the drug class, cancer type, and individual patient factors.

Response Assessment

• Imaging (CT / PET-CT / MRI): Typically performed every 8–12 weeks during the first year of targeted therapy to assess tumour response using RECIST 1.1 criteria (complete response, partial response, stable disease, progressive disease). Imaging frequency is often reduced to every 12–16 weeks once stable or complete response is confirmed.
• Biomarker monitoring: For CML, BCR-ABL1 transcript levels by RT-PCR are measured every 3 months — the gold standard for molecular response assessment. For HER2-positive breast cancer, echocardiography to monitor LVEF is mandatory every 3 months during trastuzumab therapy. For CDK4/6 inhibitors, full blood count is checked every 2 weeks for the first 2 cycles, then monthly.
• Symptom and toxicity review: Clinic visits every 4–8 weeks in the first 6 months, extending to every 3 months once the patient is established on treatment and toxicity is managed. Side effects such as rash, diarrhoea, hypertension, and fatigue are assessed and managed proactively.
• Drug level monitoring: Not routine for most targeted agents but may be performed for drugs with highly variable pharmacokinetics or when toxicity or efficacy is unexpectedly poor.

Resistance Monitoring

• Rising tumour markers, worsening symptoms, or radiological progression during targeted therapy should prompt investigation for acquired resistance mutations — ideally via liquid biopsy (ctDNA testing) to detect resistance mutations without requiring a new tissue biopsy.
• Re-biopsy of a progressing lesion (tissue) may be performed to characterise resistance mechanisms and guide selection of subsequent therapy.

Long-Term Follow-Up

• Patients achieving complete remission or treatment-free remission (as in CML) continue surveillance with periodic molecular testing and clinical review to detect any sign of disease recurrence.
• Secondary malignancies (e.g., SCC with BRAF inhibitors; MDS/AML with PARP inhibitors) require appropriate screening and surveillance.
• Cardiovascular risk monitoring is ongoing for drugs associated with hypertension, cardiac toxicity, or thromboembolic events.

Targeted cancer therapies are among the most expensive drug classes in medicine. Pricing reflects the cost of discovery, development, and clinical trial investment, as well as the relatively narrow patient populations for whom each drug is approved. However, drug costs vary dramatically by country due to national pricing negotiations, generic competition, and healthcare system structure.

Representative Annual Drug Costs (Brand/Originator, Without Insurance)

• Imatinib (Gleevec/Glivec) for CML: USD 120,000–148,000 per year in the USA. Generic imatinib: USD 300–3,000 per year (available in India, generic in USA since 2016). In India, Sun Pharma's generic imatinib costs approximately USD 500–1,000 per year.
• Osimertinib (Tagrisso) for EGFR+ NSCLC: USD 180,000–200,000 per year in the USA. EU: EUR 60,000–90,000 (after negotiation). India: USD 2,000–5,000 with generic versions or compassionate access programs.
• Trastuzumab (Herceptin) for HER2+ breast cancer: USD 70,000–100,000 per year in the USA. Biosimilars (Kanjinti, Herzuma, Ogivri) available at 70–85% of originator cost. India: USD 5,000–15,000 per year with biosimilars.
• Palbociclib (Ibrance) for HR+ breast cancer: USD 170,000 per year in the USA. Generics available in India: USD 1,500–5,000 per year.
• Venetoclax (Venclexta) for CLL: USD 170,000–200,000 per year (USA).
• Olaparib (Lynparza) for BRCA+ cancers: USD 185,000 per year (USA).

Key Cost Determinants

• Brand vs. generic or biosimilar availability (generics may cost 5–10x less)
• Country of treatment and national drug pricing agreements
• Insurance coverage (many countries cover approved targeted therapies for cancer)
• Duration of treatment (continuous therapy for years accumulates rapidly)
• Biomarker testing costs (NGS panels: USD 1,000–5,000; IHC/FISH: USD 200–800)
• Combination regimens (multiple agents multiply costs)
• Patient assistance programs: most major pharmaceutical companies offer patient support programs for qualifying patients (income-based, compassionate access)

Medical Tourism for Targeted Therapy

India has become a major destination for cancer patients seeking affordable targeted therapy. India manufactures high-quality generic versions of many targeted therapy drugs at 10–20% of Western prices. Oncology centres in Mumbai (Tata Memorial Hospital), Chennai (Apollo), Hyderabad (Yashoda, Care), and Bangalore (HCG, Manipal) offer comprehensive oncology care with full molecular testing and specialist oncologists at substantially lower cost than the USA or Western Europe.

When targeted therapy is not available (no actionable target identified), not tolerated, or has failed due to resistance, several alternative cancer treatment strategies may be considered — often in combination with one another and with targeted therapy as part of a sequential treatment plan.

Conventional Chemotherapy

Cytotoxic chemotherapy drugs (platinum compounds, taxanes, anthracyclines, antimetabolites) attack all rapidly dividing cells and remain the backbone of treatment for many cancer types where no targetable mutations have been identified (e.g., triple-negative breast cancer, extensive-stage SCLC, most sarcomas). Chemotherapy causes more side effects than targeted therapy but remains highly effective for chemosensitive tumours. It is often combined with targeted therapy (e.g., trastuzumab + pertuzumab + taxane for HER2+ breast cancer).

Immunotherapy (Immune Checkpoint Inhibitors)

Anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab, avelumab), and anti-CTLA-4 (ipilimumab) antibodies release brakes on the immune system, enabling T-cells to recognise and attack cancer cells. Immunotherapy is particularly effective in cancers with high mutational burden, MSI-H/dMMR status, or high PD-L1 expression. It is now first-line therapy for many NSCLC patients (PD-L1 > 50%), melanoma, bladder cancer, and renal cell carcinoma, and is approved across >20 cancer types. Immunotherapy can produce durable, long-lasting remissions not typically seen with targeted therapy — including potential cure in some cases of metastatic melanoma.

Hormonal / Endocrine Therapy

For hormone-receptor-positive cancers (breast, prostate, endometrial, thyroid), endocrine manipulation — reducing hormone levels (aromatase inhibitors, GnRH agonists) or blocking hormone receptors (tamoxifen, fulvestrant, enzalutamide) — is highly effective, well-tolerated, and often used before or alongside targeted therapy.

Radiation Therapy

Stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS) provide highly conformal, image-guided radiation to primary tumours and oligometastatic disease — either as a definitive treatment or to debulk residual disease after systemic therapy. Ablative radiotherapy to oligoprogressive lesions during targeted therapy can extend the duration of systemic drug benefit.

Surgery

Surgical resection of the primary tumour or operable metastases remains an important option, particularly when targeted therapy has downstaged initially inoperable disease to a resectable state (e.g., EGFR TKI neoadjuvant therapy converting unresectable NSCLC to resectable).

Clinical Trial Enrolment

For patients who have exhausted standard targeted therapy options, enrolment in clinical trials of novel agents, combination strategies, or biomarker-driven basket trials may provide access to next-generation therapies not yet approved. Oncology centres conducting active trial programs should be consulted for all patients with refractory disease.